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Schizophrenia (SZ) is a debilitating condition wherein those afflicted experience positive 
symptoms, including hallucinations and delusions, as well as negative symptoms, 
including alterations of processing affecting cognition and social interactions. The 
NMDA receptor hypofunction model of SZ asserts that a reduction in hippocampal 
NMDA receptor input produces the pathology of this disorder, promoting excessive 
frontocortical excitatory neurotransmission – particularly overstimulation of basal 
forebrain cholinergic neurons – that ultimately impairs cognitive and sensorimotor 
processes. Orexin-A (OxA), a neuropeptide principally involved in wakefulness and 
appetitive behaviors, has been shown to demonstrate cognitive-enhancing qualities in 
models of psychiatric and neurodegenerative illness. In the present study, the effects of 
OxA on attentional performance were examined in a NMDA receptor antagonist model 
of SZ. Male Fischer 344 Brown Norway F1 Hybrid rats (N = 12) received both 
intraperitoneal injections of MK-801 and intranasal administration of OxA prior to 
placement in a sustained attention task requiring differentiation between signal trials 
(500, 100, and 25ms illumination of a central panel light) and non-signal trials (no light 
illumination). Overall, it was shown that the highest dose of OxA exacerbated MK-801-
induced attentional deficits. While the small OxA concentration slightly protected against 
impairments in the correct rejection of the signal and increased omission rates at the 
low dose of MK-801, this excitatory neuromodulator was largely unable to improve 
performance in the attention task. These findings suggest that, in a state of cortical 
hyperexcitation like what is observed both in SZ and following NMDA receptor 
antagonism, the introduction of pharmacotherapies augmenting activity at the 
orexinergic system further exacerbates existing cognitive dysfunction in lieu of 
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Chapter 1: Introduction and Research Hypotheses 
Overview 
 The debilitating and complex condition known as schizophrenia (SZ) is a 
chronic disorder of the nervous system. As described in the fifth edition of the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-5), SZ is comprised 
of five primary symptoms: delusions, hallucinations, muddled speech, 
disorganized or catatonic behavior, and negative symptoms. Despite a low 
incidence of diagnosis – with only 1% of the world’s population being affected at 
a given time – those with SZ can experience a tremendously reduced quality of 
life due to the severity of the symptoms (Faris & Dunham, 1939). The 
experiences and behaviors associated with schizophrenia have historically been 
dichotomized into “positive” and “negative” symptoms. Positive symptoms reflect 
experiences or behaviors that should not normally be present. This class of 
symptoms includes hallucinations, delusions, and disorganize thoughts and have 
been classically treated using antipsychotic medications in tandem with 
counseling. The severity of affective, cognitive, and social impairments – together 
called negative symptoms because they denote a deficit in normal behaviors – 
are notoriously difficult to ameliorate and are more strongly associated with poor 
treatment outcomes than are the positive symptoms (Tamminga, Buchanan & 
Gold, 1998). While classically categorized as negative symptoms, cognitive 
impairments including attention, learning, and memory deficits are occasionally 
organized separately from the positive and negative symptoms and are 
considered their own distinct group (Bowie & Harvey, 2006). The Positive and 
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Negative Syndrome Scale (PANSS), first described by Stanley Kay, Abraham 
Fiszbein, and Lewis Opler in 1987, allows clinicians to measure the severity of 
the two distinct categories of SZ symptoms in the context of the global 
psychopathology.  
Schizophrenia and the dopamine hypothesis  
The pathology of SZ is a result of the dysregulation of multiple brain 
networks, and parsing out the underlying neurological mechanisms inciting these 
imbalances has been a challenge. For the last 50 years, the dopamine (DA) 
hypothesis has provided informative insight into the investigation of the etiology 
of the condition. The premise of this model proposes that the development and 
symptoms of the disorder emerges from both subcortical hyperdopaminergia and 
cortical hypodopaminergia (Howes & Kapur, 2009; Davis et al., 1991). Previous 
findings have shown that there is an increase in expression and density of the 
presynaptic dopamine-2 receptor (D2R) subtype, which enhances DA 
neurotransmission upon stimulation, in extrastriatal regions of the SZ-afflicted 
brain, including the substantia nigra, ventral putamen, and nucleus accumbens 
(Wong et al., 1986; Joyce et al., 1988; Seeman & Kapur, 2000). Radioligand 
binding and positron emission studies have also revealed a substantial loss of 
cortical D1Rs in the prefrontal cortices of SZ patients, and the extent of the loss 
is correlated to the severity of the cognitive impairment (Okubo et al., 1997; Abi-
Dargham et al., 2002; Guo et al., 2003). Augmented DA activity in the striatum 
and dampened DAergic neurotransmission in the cortex induces the positive and 
negative symptomologies, respectively (Brozoski et al., 1979; Davis et al., 1991). 
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Both typical and atypical antipsychotics inhibit the activity of D2-like receptors in 
the mesolimbic pathway, including the D2R as well as D3 and D4 receptor 
subtypes (Kapur & Seeman, 2001; Burstein et al., 2005). In support of this 
model, the degree to which a given neuroleptic occupies presynaptic D2Rs in 
subcortical regions tends to predict its therapeutic efficacy (Seeman & Lee, 1975; 
Creese, Burt & Snyder, 1976). Many second-generation antipsychotics assuage 
DAergic hyperexcitation by antagonizing serotonin-2 receptors (5-HT2Rs) in 
addition to D2Rs; by de-emphasizing their affinities to DA receptors and acting 
more potently in in the 5-HTergic system, these drugs are able to alleviate SZ 
symptoms with similar efficacy while minimizing extrapyramidal side effects 
(Kuroki, Nagau & Nakahara, 2008; Leucht et al., 2009). 
Despite having prevailed as the chief paradigm in the study of SZ of the 
last several decades, the DA hypothesis does not encompass all facets of the 
disorder; namely, there is not sufficient evidence to suggest that targeting DA 
dysregulation effectually ameliorates the pathology in its entirety. While 
antipsychotic medications tend to effectively normalize DA concentrations and 
adequately assuage the severity of psychosis, they take several weeks to exert 
their therapeutic effects while failing to improve the cognitive and social deficits 
(Kapur et al., 2006). In addition to this, around 30 percent of those diagnosed are 
classified as treatment-resistant, determined by little to no responsiveness to at 
least two neuroleptics (Meltzer, 1997). Those who demonstrate a reduction in 
positive symptomology resulting from antipsychotic therapy may still experience 
the brunt of the negative syndrome. This inability of antipsychotic therapies
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 primarily targeting DAergic neurons in reducing the catatonia, anhedonia, 
and withdrawal associated with SZ necessitates the exploration of other major 
neuromodulatory networks in its etiology and treatment.  
N-methyl-D-aspartate receptors in SZ 
In response to newly-available data as well as the widespread 
shortcomings of the DA hypothesis, a new model centered around glutamatergic 
dysregulation was posited. Following the discovery of markedly reduced N-
methyl-D-aspartate receptor (NMDAR) signaling in individuals with SZ by Kim 
and colleagues in 1980, and later supported by findings demonstrating reduced 
NR1 subunit mRNA in postmortem hippocampal tissue from SZ-afflicted 
individuals when compared to healthy controls, an alternate hypothesis emerged 
that attempted to incorporate this network into understanding the origins of the 
widespread corticolimbic neurotransmitter imbalances (Gao et al., 2000; Clinton 
& Meador-Woodruff, 2004). This model suggests that schizophrenic 
symptomology is a byproduct of an underactive NMDAR system, disabling the 
excitatory-inhibitory feedback loop and inciting extensive aberrations in glutamate 
release. NMDAR hypofunction also disrupts other neurotransmitter systems, 
particularly DAergic, 5-HTergic, and cholinergic networks (Kapur & Seeman, 
2002). In large part, this NMDAR hypofunction model attempts to offer an 
alternative to the typical neuroleptic medications that fail to remedy the cognitive, 
social, and affective deficits. The NMDA hypofunction model suggests that 
therapeutics targeting the glutamatergic system, which may also normalize DA 
levels, could further improve treatment outcomes for these individuals. 
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NMDARs are iontropic glutamate receptors (iGluRs) that are expressed in 
numerous brain regions, including the neocortex, ventral striatum, hippocampus, 
amygdala, and, to a lesser extent, the thalamus (Meador-Woodruff & Healy, 
2000). Glutamate, being the primary endogenous ligand that depolarizes these 
receptors, is the main excitatory neurotransmitter in the brain and facilitates the 
majority of all excitatory neurotransmission in the mammalian nervous system 
(Traynelis et al., 2010). NMDARs themselves are either di- or tri-heteromeric in 
nature, being comprised of an NR1 subunit – to which glutamate has an affinity – 
as well as an NR2 glutamate-binding subunit and/or an NR3 glycine-binding 
subunit (Schüler et al., 2008). With cell bodies originating in the ventral 
hippocampus, the glutamatergic system is composed of NMDARs as well as α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs), 
kainate receptors, and eight metabotropic glutamate receptor (mGluR) subtypes 
(Nakanishi, 1992; Ferraguti & Shigemoto, 2006). The stimulation of these 
glutamatergic receptor subtypes incites excitatory post-synaptic potentials 
(EPSPs) and is vital for mediating various aspects of neural plasticity and 
cognition (Li & Tsien, 2009). In particular, the CA1 region of the hippocampus is 
densely packed with NMDARs and is necessary for long-term potentiation (LTP), 
the synapse-strengthening process by which a wide array of cognitive processes 
are facilitated (Collingridge & Bliss, 1987). 
          In general, the suppression of hippocampal NMDAR signaling significantly 
reduces synaptic plasticity, producing cognitive deficits ranging from attentional 
processing to long-term memory storage in both human and non-human 
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paradigms (Tsien, Huerta & Tonegawa, 1996). Interestingly, the blockade of 
NMDA receptors induces a state of cortical hyperexcitation. NMDAR 
hypofunction boosts the extracellular release of endogenous excitatory 
neurotransmitters, including glutamate and aspartate, which greatly augment the 
stimulation of post-synaptic non-NMDA glutamatergic receptors, particularly in 
the prefrontal cortex (PFC) (Moghaddam & Javitt, 2011). This general 
hyperexcitation, in turn, diminishes the signal-to-noise ratio in cortical regions 
associated with cognition (Bustos et al., 1992; Liu & Moghaddam, 1995; 
Moghaddam et al., 1997). This conclusion has been supported by research 
suggesting that there is an increased quantity of cortical glycine-binding sites 
resulting from impaired glutamate neurotransmission in the brains of SZ patients 
(Ishimaru, Kurumaji & Toru, 1992; Ishimaru, Kurumaji & Toru, 1994). As a 
consequence of the overstimulation of non-NMDA glutamate receptors, the 
release of other excitatory monoamines – particularly dopamine (DA) and 
serotonin (5-HT) – is greatly augmented in the PFC and, to a lesser extent, the 
striatum. Therefore, excessive glutamatergic activity increases frontocortical 
noise itself as well as through the promotion of the release of other excitatory 
ligands.  
          One potential explanation for the excessive cortical activation observed 
following NMDAR hypoactivation involves the impairment of fast-spiking cortical 
interneurons (Wilson et al., 1994; Markram et al., 2004; Homayoun & 
Moghaddam, 2007). In the neurotypical brain, the interaction of glutamatergic 
and GABAergic systems acts as an effective “acceleration” and “brake” system, 
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respectively, by which excitatory neurotransmission is regulated, helping to 
maintain homeostatic signal transduction in cortical regions through a continuous 
feedback loop (Carlsson et al., 2001). The overstimulation of NMDARs elicits the 
GABAergic response, dampening excitatory neurotransmitter input to the cortex; 
similarly, the underactivation of the glutamatergic system decreases the inhibitory 
effects of the GABA interneurons. The suppressant function of GABA receptors 
(GABARs) on the activity of glutamate and other excitatory neuropeptides is 
dependent on adequate NMDAR input. Studies using microdialysis to examine 
GABAergic outflow after the pharmacological blockade of NMDARs have 
demonstrated that a hypofunctioning NMDAR system induces dysfunction in the 
regulatory actions and spontaneous firing rate of these putative GABA 
interneurons. GABAergic suppression disrupts the ability of these neurons to 
lessen excitatory outflow to the cortex, leading to excessive stimulation of 
prefrontal pyramidal neurons (Homayoun & Moghaddam, 2007). The failure of 
these inhibitory mechanisms impairs a variety of cognitive processes through the 
malfunction of excitatory neuromodulator activity and excessive frontocortical 
activation.  
Findings from studies using an assortment of cognitive and behavioral 
assays have illustrated a relationship between NMDAR inhibition and deficits in 
vigilance, learning, and memory. For example, Sakimura et al. (1995) showed 
that mice with NR2A subunit gene disruption demonstrated substantially reduced 
hippocampal LTP, negatively impacting spatial memory performance when 
compared to wild-type mice. In a similar fashion, Bannerman and colleagues
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(2013), while failing to discern disparities in spatial memory performance 
following deletion of CA1 NMDARs in the dentate gyrus and dorsal hippocampus, 
observed deficits in the utilization of spatial information to make navigation-
related decisions in a water maze. In contrast to the previous experiment, Tsien, 
Huerta, and Tonegawa (1996), using CA1 NMDAR knockout mice, confirmed 
that the lack of this gene leads to a disruption in learning in the Morris water 
maze as well as impaired spatial memory as measured by increased escape 
latencies in the task.  
          The pharmacological inhibition of NMDARs yields similar behavioral 
outcomes when compared to the genetic deletion of these receptors. Ketamine, a 
dissociative anesthetic, is a non-competitive NMDAR antagonist known to reduce 
calcium influx by binding inside of the ion channel, suppressing its overall firing 
rate (Malhotra et al., 1996). Phencyclidine (PCP), similarly classified as a non-
competitive NMDAR channel blocker, also produced dysfunctions in 
frontocortical excitatory neurotransmission and disturbed cognitive performance 
during tasks dependent on balanced catecholamine concentrations in the PFC 
(Zukin & Zukin, 1979; Morris, Cochran & Pratt, 2005). NMDAR antagonism 
particularly exacerbates prefrontal DAergic activity, as the excessive stimulation 
of non-NMDA glutamate receptors induces endogenous DA release 
(Moghaddam et al., 1997). The glutamatergic-mediated augmentation of DA and 
other monoamine concentrations in brain areas implicated in attention, learning, 
and both working and long-term memory suggests that excitatory transmission 
promotes cognition to a certain extent, but excessive excitatory activity becomes 
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counterproductive in this regard, and NMDAR blockade incites hyperexcitation-
related deficits. 
It has been speculated that impairment in NMDAR and non-NMDA 
glutamate receptor function in the SZ brain contributes to profound cognitive 
deficits. As has been confirmed by evidence from transcranial magnetic 
stimulation (Rogasch, Daskalakis & Fitzgerald, 2014) and ligand binding (Deakin 
et al., 1989) studies, there is overstimulation of glutamatergic afferents and an 
increase in glutamatergic binding in cortical regions of the schizophrenic brain, 
largely due to systematic failure of GABA interneuron-mediated cortical inhibition. 
Rogasch, Daskalakis and Fitzgerald (2014) also revealed diminished long-range 
corticolimbic connectivity in these individuals associated with aberration in small 
populations of neurons that interact with these connections. General prefrontal 
function is markedly reduced in SZ as well, and Beneyto et al. (2007) suggest 
this may be largely due to reduced function of NMDAR afferents and their 
contribution to numerous cognitive processes. Following this logic, drugs that are 
able to ameliorate frontocortical hyperexcitation induced by dampened cortical 
NMDAR inputs may be able to lessen SZ symptomology, particularly when 
considering the negative cognitive, affective, and social tendencies. 
The cholinergic system and schizophrenia 
        Cholinergic neurons, which release the neurotransmitter acetylcholine (ACh) 
throughout the nervous system, are required for a wide variety of psychological 
and behavioral phenomena. Being comprised of both ionotropic nicotinic ACh 
receptors (nAChRs) and metabotropic muscarinic ACh receptors (mAChRs), 
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activation of the basal forebrain cholinergic system (BFCS) in the typically-
functioning brain enhances cognition (Drachman, 1977). ACh efflux is particularly 
elevated during attentionally-demanding tasks, with cortical cholinergic 
projections playing a major role in mediating sustained attentional processing 
and allocating vigilance-related resources (Sarter, Gehring & Kozak, 2006; 
Dumas & Newhouse, 2011). The cholinergic network is especially involved in the 
top-down, knowledge-based processing of relevant environmental stimuli as well 
as the deemphasis of irrelevant information, and this process interacts with the 
bottom-up input of sensory information to improve attentional performance 
(Sarter et al., 2001). The degree to which a particular task is attentionally-
demanding dictates the extent of basal forebrain cholinergic activation. The 
ability of this system to filter out extraneous and distracting information while 
simultaneously enhancing the detection of relevant stimuli makes the integrity of 
corticopetal cholinergic projections required for attention and the processes that 
depend on it, such as learning and working memory.  
In the same vein, compromised cholinergic neurotransmission has been 
linked to impairments in basic cognitive functioning, and dampened function of 
cortical cholinergic innervation is a chief contributor to both age-related cognitive 
impairments and those seen in individuals with neurodegenerative conditions 
such as Alzheimer’s and Parkinson’s diseases (Coyle, Price & DeLong, 1983; 
Perry et al., 1985; Everitt & Robbins, 1997). Similarly, suppression of basal 
forebrain corticopetal neurons with cholinergic antagonists or the immunotoxin 
192 IgG-saporin, for example, produces marked deficits in a number of measures 
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relating to cognition, including visual attention and memory formation 
(McGaughy, Kaiser & Sarter, 1995; Chudasama et al., 2004; Burk, Lowder & 
Altemose, 2008; Hasselmo & Sarter, 2011).  
Overactivation of these receptors impairs cognition as well, adhering to the 
“inverted-U” phenomenon of neuronal stimulation. When considering the dose-
response association between BFCS activation and behavior, this parabolic 
relationship suggests that both sub-threshold and elevated ACh levels have a 
counterproductive impact on a variety of physiological and psychological 
processes while moderate levels of activation demonstrate beneficial qualities 
(Picciotto, 2003). In the typically-functioning brain, reduced concentrations of a 
cholinergic ligand do not tend to elicit effects on behavior, but too high of a 
concentration can overstimulate these receptors and induce a hypercholinergic 
state. Excessive output from basal forebrain neurons has been shown to diminish 
the cortical signal-to-noise ratio and bolster sensory stimuli-evoked discharge, 
inciting disturbances in both cognitive and sensory processes (Donoghue 
&Carroll, 1987; Perry & Perry, 1995). The capacity for potent cholinergic agents 
to dampen both bottom-up and top-down processing of cognitive and sensory 
information further validates the necessity of the BFCS in modulating intellectual 
and perceptual systems. 
  Because of the crucial role this system plays in cognitive functioning, 
dysregulation of basal forebrain projections to the cortex is suggested to 
contribute to the pathology of SZ. Previous research examining cholinergic 
receptors in the etiology of SZ support the notion that cholinergic output from the 
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basal forebrain is elevated in the SZ brain, likely contributing to both the positive 
and negative symptoms of the disorder (Tandon & Greden, 1989). Glutamate 
receptors are located on basal forebrain corticopetal cholinergic neurons. Thus, 
these cortically projecting cholinergic neurons show an elevated firing rate in the 
presence of augmented glutamate release resulting from NMDAR regulatory 
failure (Fadel, Sarter & Bruno, 2001). In a state of cortical hyperexcitation 
induced by NMDAR and GABAR hypofunction, amplified ACh release has been 
shown to reduce performance in a wide variety of cognitive measures. As 
discussed by Tandon and Greden (1989), for individuals with SZ, excessive 
frontocortical cholinergic activity – believed to stem predominantly from mAChR 
overactivation – diminish attentional performance by increasing the perception 
and processing of irrelevant stimuli. In congruence with this idea, the atypical 
antipsychotic medication clozapine is believed to elicit some of its therapeutic 
effects through mAChR antagonism (Bolden, Cusack & Richelson, 1991; Meltzer 
& McGurk, 1999). Finally, both the density of and the binding at nAChRs and 
mAChRs are significantly decreased throughout cortical and striatal structures of 
the schizophrenic brain (Durany et al., 2000; Crook et al., 2001; Marutle et al., 
2001; Terry, 2008; Scarr et al., 2009). This reduction in receptor reactivity is likely 
a product of their desensitization, as is known to occur following chronic 
cholinergic overstimulation (Nastuk & Wolfson, 1976). 
One very common and accessible way by which individuals with SZ are 
speculated to self-medicate is by smoking cigarettes. While 25 to 30 percent of 
the general population smokes on a regular basis, anywhere from 80 to 90% of 
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those afflicted with SZ are habitual cigarette smokers (Ripoll, Bronnec & Bourin, 
2004). Nicotine, the primary psychoactive ingredient in cigarettes, is known to 
demonstrate cognition-enhancing characteristics for those with and without a 
diagnosis of SZ; interestingly, however, the mechanisms underlying nicotine’s 
beneficial qualities for people with SZ differ from those with a neurotypical brain. 
In particular, nicotine is considerably more reinforcing for those with SZ due to its 
capacity to temporarily relieve sensory and cognitive disturbances exacerbated 
by superfluous cholinergic activity. Nicotine administration has been shown to 
normalize deficits in inhibitory sensorimotor gating, including P50 auditory gating 
and prepulse inhibition (Siegel et al., 1984; Adler et al., 1993). When considering 
measures of cognition, following a period of forced abstinence in a study 
conducted by Sacco and colleagues (2005), habitual smokers with SZ performed 
more poorly on sustained attention and spatial working memory tasks than non-
schizophrenic smoking controls. These impairments in performance were 
alleviated following reinstatement of cigarette-smoking; if those with SZ were pre-
treated with mecamylamine hydrochloride, a non-selective nAChR antagonist, 
nicotine failed to alleviate these cognitive deficits.  
 There are a number of ways through which nicotine administration is able 
to normalize dysregulated excitatory neurotransmission in the brains of persons 
with SZ. One method involves targeting low-affinity alpha-7 (α7) nAChRs, which 
have been shown to augment NMDAR firing. Nicotine exerts its effects 
presynaptically, thereby releasing glutamate onto postsynaptic NMDARs. A 
synergistic effect has been observed when α7 nAChRs and NMDARs are 
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simultaneously stimulated (Aramakis & Metherate, 1998). Many hippocampal α7 
nAChRs both terminate onto and share synapses with voltage-gated NMDARs, 
suggesting that activity at this nAChR subtype modulates glutamate-induced 
excitatory post-synaptic potentials to a degree (Zappetini et al., 2014). Armakis 
and Metherate go on to suggest that, in effect, α7 nAChR stimulation may be 
required for these particular NMDARs to activate. Zappettini et al. (2014), by 
utilizing a non-metabolizable tracer, calcium imaging, and immunocytochemical 
assays to quantify the impact of nicotine pre-exposure on NMDAR activation, 
revealed that the increase in NMDAR-mediated glutamatergic outflow is present 
in the nucleus accumbens (NAcc) and, to a slightly lesser extent, hippocampal 
nerve terminals. This effect was not present following stimulation of alpha-4 beta-
2 (α4β2) nAChRs, as this receptor subtype was found to reduce presynaptic 
GluN2B-containing NMDAR activation when agonized. In the context of the 
NMDAR hypofunction model of SZ, pharmacotherapies that stimulate normally 
underactive NMDARs, such as α7 nAChR agonists, may help to normalize 
frontocortical excitatory neurotransmission.  
 The crucial interaction between NMDARs and nAChRs is further validated 
by studies examining the behavioral effects of nicotine and similar compounds 
following NMDAR blockade. For instance, nicotine administration ameliorates 
deficits in prepulse inhibition induced by PCP, denoting its therapeutic potential 
for alleviating sensorimotor dysregulation (Spielewoy & Markou, 2004). Mice 
given the α7 nAChR agonist SSR180711 for two weeks following a ten-day 
period of sub-chronic PCP administration demonstrated significantly improved 
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performance in a novel object recognition test compared to those given saline 
after PCP exposure (Hashimoto et al., 2008). Mice that were systematically 
administered the potent NMDA receptor antagonist MK-801 prior to placement in 
a fear conditioning task were able overcome NMDAR blockade-induced learning 
deficits when also receiving bilateral nicotine infusions (André, Leach & Gould, 
2011). Yang et al. (2013) antagonized α7 nAChRs in the dorsolateral PFC and 
discovered that, largely through the suppression of NMDAR activity, there was a 
marked reduction in the attentional modulation of the visual cortex and, therefore, 
representation of space in the primate. Low doses of nicotine, however, 
enhanced these visual representations. Thus, due to the interactions between 
these two networks, α7 nAChR stimulation is able to remediate cognitive deficits 
resulting from suppression of NMDAR activation.  
 Another potentially beneficial aspect of nicotine that helps to alleviate 
frontocortical hyperexcitation involves reducing elevated ACh levels via 
GABAergic stimulation. Cholinergic neurons from the basal forebrain innervate 
the hippocampus through the septo-hippocampal pathway, which is a bi-
directional network that modulates ACh release primarily through the activation of 
GABAR projections to the BFCS (Dutar et al., 1995; Khakpai et al., 2013). 
Stimulation of α7 nAChRs has shown to inhibit basal forebrain cholinergic activity 
through the promotion of GABAergic input from these hippocampal innervations 
(Alkondon et al., 2000; Maggi, Sher & Cherubini, 2001). Through the mild 
suppression of corticopetal cholinergic activity, cortical overstimulation in SZ can 
be quelled and some aspects of cognition can be temporarily restored. Agonists 
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that target the α7 nAChR subtype demonstrate similar cognition-boosting 
properties as well, and such drugs have been suggested to offer promise as both 
monotherapy and adjunct therapy for SZ (Martin, Kem & Freedman, 2004). 
Nicotine is also well-known to boost DA release in the NAcc, ventral tegmental 
area (VTA), and PFC, helping to address the problem of hypofrontality in SZ 
patients (Corrigall & Coen, 1991; Corrigall, Coen & Adamson, 1994; Dalack, 
Healy & Meador-Woodruff, 1998).  
One issue with nicotine, however, is that it more effectively stimulates 
α4β2 nAChRs compared to α7 nAChRs. Because activity at α4β2 nAChRs 
promotes cholinergic neurotransmission, symptoms related to psychosis can be 
worsened by cigarette smoking and nicotine self-administration. Not only is the 
α4β2R subtype more commonly expressed than its α7 counterpart, but both 
nicotine and the endogenous ligand bind more efficiently to these receptors (De 
Luca et al., 2006). The α4 subunit of the α4β2 nAChR is especially implicated in 
striatal basal DA release, largely contributing to nicotine’s rewarding qualities for 
smokers both with and without SZ. While activity at α7 nAChRs may alleviate 
some of the symptoms of SZ – namely those related to cognition – it may also 
increase the likelihood of a psychotic episode, mediated primarily through the 
exacerbation of already-elevated mesolimbic DA concentrations. This idea is also 
supported by the capacity for nicotine to diminish the antagonist effects of 
antipsychotics at D2Rs by augmenting cortical DA release, occasionally 
necessitating an increase in dosage of these drugs (Pierre, 2005). 
Measurements of DA efflux resulting from nAChR activation following systematic 
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intracranial infusions of nicotine revealed that, over time, less cortical DA was 
being released following nicotine due to the desensitization of both nAChRs and 
DARs (Marks, Grady & Collins, 1993). Thus, while demonstrating some transient 
cognition-enhancing properties, nicotine as a method of self-medication is 
unsuitable as a long-term treatment option.  
The orexinergic system and SZ  
 The orexinergic network is believed to play a crucial role in cognition. Also 
called hypocretins, orexins are considered the primary wakefulness 
neuromodulators in the brain, acting as a regulator of both circadian and 
appetitive processes (Sakurai et al., 1998; Saper, Scammell & Lu, 2005). This 
neuronal network, which is comprised of  approximately 70,000 neurons in 
humans and originates in the lateral hypothalamus and adjacent perifornical area 
(PFA), was first discovered in 1996 by Gautvik, de Lecea and colleagues and 
later classified by both de Lecea and Sakurai in separate studies in 1998. The 
orexinergic system consists of orexin-A (OxA) and orexin-B (OxB) endogenous 
isoforms (collectively referred to as orexins), derived from the same amino acid 
precursor prepro-orexin, as well as G-protein coupled orexin-1 (Ox1R) and 
orexin-2 (Ox2R) receptors. While OxB has low affinity to Ox1Rs and elicits most 
of its effects through Ox2R stimulation, OxA displays equally potent activation of 
both Ox1Rs and Ox2Rs (Hagan et al., 1999). OxA and OxB induce a biphasic 
calcium response when binding at orexinergic receptors, both releasing 
intracellular calcium via phospholipase C as well as promoting an influx of 
calcium from the extracellular space (Smart et al., 1999). Unlike other 
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hypothalamic neuropeptides, OxA and OxB have been shown to   facilitate the 
release of both GABA and glutamate when acting at axon terminals, which, 
together, regulate virtually all hippocampal excitatory neurotransmission (van den 
Pol et al. 1998; Chemelli et al., 1999).  
As has been established in both in vitro and in vivo recording studies, C-
fos expression in orexin neurons is highest during the day hours in diurnal 
animals, increasing feelings of wakefulness and promoting hunger, whereas 
without exposure to daylight cues, the activity of the orexinergic network is 
suppressed and both arousal and food-seeking behaviors are reduced (Willie et 
al., 2001). In fact, these cells must be effectively “switched off” to maintain both 
consolidated NREM stages and the muscular atonia associated with REM sleep 
(Sakurai, 2007). Activity of these cells is transiently augmented following sensory 
stimulation and emotional perturbance, suggesting that the system is markedly 
sensitive to sensorimotor processes and psychological drives (Mileykovskiy, 
Kiyashchenko & Siegel, 2005). For those with narcolepsy, hypofunctioning 
Ox1Rs and especially Ox2Rs generate abnormal patterns of arousal, inducing 
daytime somnolence in addition to frequent bouts of cataplexy and 
unconsciousness (Lin et al., 1999). Those that suffer from narcolepsy and related 
sleep disorders also tend to demonstrate deficits in cognitive performance (Fulda 
& Schulz, 2001). The necessity of the orexinergic activation in regulating 
circadian rhythmicity and maintaining an enduring state of wakefulness suggests 
that OxA and OxB are two significant neurological correlates of consciousness; 
thus, it can be postulated that this system likely contributes in some capacity to 
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the cognitive processes that are enhanced in a state of increased arousal and 
alertness. 
 In support of this proposition, stimulation of Ox1Rs and Ox2Rs have been 
found to improve attention, learning, and working memory, primarily by instigating 
the release of wakefulness-promoting and cognition-enhancing neuropeptides. 
The orexinergic system projects all throughout the brain and interacts with not 
only structures related to consciousness, but many midbrain and forebrain 
structures implicated in cognitive processes, such as the locus coeruleus, 
amygdala, paraventricular nucleus of the thalamus, VTA, and infralimbic and 
prelimbic prefrontal cortical areas (Peyron et al., 1998; Ebrahim et al., 2002; 
Fadel & Deutch, 2002). In neurotypical, well-rested organisms, targeting OxRs 
has negligible effects on attentional and cognitive performance, likely due to the 
normal activation of this network. However, in sleep-deprived individuals, 
administration of OxA alleviates cognitive impairment induced by lack of sleep 
(Deadwyler et al., 2007). Similarly, the inhibition of Ox1Rs has been 
demonstrated to impair cognition. Rats given both systematic and intrabasalis 
SB-334867, an Ox1R antagonist, and placed in a sustained attention task 
revealed substantial reductions in the ability to correctly identify the occurrence of 
a brief visual stimulus (Boschen, Fadel & Burk, 2009; Fadel & Burk, 2010). The 
suppression of sustained attentional capacity elicited by Ox1R antagonism is 
similar to that observed follow loss of basal forebrain corticopetal cholinergic 
neurons. The inactivation of these neurons with SB-334867, too, precludes 
acquisition, consolidation and retrieval of spatial memories related to 
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performance in the Morris water maze, highlighting the importance of the 
orexinergic system at multiple stages of cognition (Akbari, Naghdi & Motamedi, 
2006).  
 Hypothalamic orexinergic neurons are thought to play an important 
modulatory role in cognition enhancement, in part, because they augment 
excitatory neurotransmitter levels, including norepinephrine (NE), histamine, and 
especially DA in the mesocorticolimbic DA circuit (Peyron et al., 1998). The 
BFCS is innervated by lateral hypothalamic orexinergic fibers (Nambu et al., 
1999). Findings from ultrastructural and light microscopy studies have found that 
around 70% of medial septal cholinergic neurons contain orexin immunoreactive 
appositions on their dendrites or cell bodies (Wu et al., 2004; Fadel, Pasumarthi 
& Reznikov, 2005; Fadel & Frederick-Duus, 2008). While both Ox1Rs and Ox2Rs 
are found throughout the basal forebrain, Eggermann and colleagues (2001) 
speculate that, because OxB administration more effectively depolarizes 
cholinergic neurons when compared to OxA, Ox2Rs are more highly expressed 
in this region and are primarily responsible for the cholinergic effects of 
orexinergic activation. Fadel and Burk (2010) propose that projections of orexin 
neurons to the basal forebrain create an anatomical substrate for the relationship 
between arousal and attention, augmenting the release of ACh to the cortex and 
promoting a state of alertness and vigilance. The activation of the cortex via 
orexin-mediated cholinergic release is believed to underlie the cognition-
promoting characteristics of compounds that boost activity at this system. 
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 OxA has also demonstrated nAChR-stimulating properties. By using two-
photon imaging and examining slices from rat PFCs, Lambe et al. (2005) were 
able to reveal a sizeable amount of shared thalamocortical synaptic activity in the 
PFC following both OxB and nicotine administration. Due to the measurably 
similar actions of these two receptor systems, it may be the case that orexins 
would have similar stimulatory and cognition-enhancing effects as nicotine. To 
test this possibility, Lambe and colleagues bilaterally infused nicotine and OxB 
into the medial PFC of rats engaged in an attention task which assessed 
detection of a 0.3 s or 1 s visual stimulus. Task accuracy was significantly 
increased by both nicotine and the larger of two OxA doses, compared to saline, 
during trials with the shorter signal duration. As such, by examining both neural 
activity and attentional processing, it has been confirmed that, to a large extent, 
OxA is able to activate the thalamocortical arousal pathway in a similar manner 
as nAChR stimulation. Additionally, nicotine consumption increases Fos 
expression in orexin-containing neurons of the hypothalamus, potentially 
underlying some of the therapeutic benefits of cigarette smoking in SZ 
(Pasumarthi, Reznikov & Fadel, 2006).  
 Despite the propensity for this network to promote cognition when 
activated, limited research has been conducted regarding the contribution of 
these neurons in SZ symptomology, particularly the negative symptoms. Chien et 
al. (2015) measured plasma concentrations of OxA of individuals with and 
without a diagnosis of SZ and discovered that OxA levels were substantially 
higher in a small subset of SZ-afflicted persons. Compared to SZ patients with 
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typical OxA levels, those in the group with elevated OxA plasma concentrations – 
comprising around 20 percent of the sample – displayed less cognitive and 
disorganized symptoms as determined by a substantial reduction in preservation 
errors on the Wisconsin Card Sorting Test (WCST), suggesting that increased 
orexinergic activity may be able to attenuate the negative syndrome. While the 
behavioral effects of orexins or orexin-like analogs have not been examined in 
models of SZ, it has been shown that modafinil, a wakefulness-promoting agent 
that augments the release of hypothalamic histamine through orexinergic 
stimulation, alleviates cognitive and attentional deficits in individuals with SZ 
(Ishizuka et al., 2003; Turner et al., 2004; Hunter et al., 2006). However, as 
modafinil acts in a variety of ways, including blocking the reuptake of DA, its 
cognition-enhancing properties cannot be attributed solely to the activation of this 
system, necessitating the exploration of pharmacotherapies acting primarily at 
Ox1Rs and Ox2Rs in the context of SZ. 
Research hypotheses  
 Since the discovery of orexins in the 1990’s, a wealth of useful information 
has been uncovered regarding the capacity of orexins to induce wakefulness and 
increase appetite. More recently, the role of OxA in cognition was detailed, and 
due to its cognition-enhancing qualities, it has been suggested to potentially 
alleviate the cognitive deficits associated with SZ. Because the negative 
syndrome is notoriously treatment-resistant and correlates strongly with poor life 
outcomes, there is an impetus to explore the potential of this cognition-enhancing 
neuropeptide in alleviating these pervasive symptoms. As was previously 
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detailed, the NMDAR hypofunction hypothesis of SZ suggests that cognitive and 
perceptual abnormalities emerge from a marked reduction in hippocampal 
NMDAR input, inducing GABAergic dysfunction and significantly augmenting 
frontocortical excitatory neurotransmission. A commonly-utilized method to 
reproduce this effect in rodents is with the administration of NMDAR antagonists, 
as these drugs have demonstrated the ability to emulate many of the 
neurological and behavioral abnormalities that are present in those with SZ 
(Mohn et al., 1999; Coyle, 2012).    
 While dopaminergic agonists such as amphetamines are effective in 
emulating the positive syndrome of SZ, NMDAR antagonists have demonstrated 
the capacity to encompass both positive and negative aspects of this disorder 
(Luby et al., 1959; Snyder, 1980). By binding to a hydrophobic site within the ion 
channel, these drugs effectively preclude the depolarization of NMDARs. 
Compounds frequently utilized in pharmacological models of SZ include 
ketamine, PCP, and MK-801 (Kapur & Seeman, 2002). MK-801, also referred to 
as dizocilpine, is the most potent NMDAR antagonist of the three and has 
demonstrated the capacity to elicit widespread social, cognitive, and perceptual 
dysregulation associated with SZ. At sufficient doses, typically at or exceeding 
0.1 mg/kg, MK-801 administration produces social withdrawal (Rung et al., 
2005), attentional deficits (Howe & Burk, 2007), learning and memory impairment 
(Butelman, 1989; de Lima et al., 2005), and motor aberrations including 
hyperactivity (Hargreaves & Cain, 1992) in rodents. Due to the robustness of this 
powerful NMDAR antagonist in accurately emulating the psychological and 
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behavioral irregularities frequently observed in patients with SZ, MK-801 was 
selected to reproduce the NMDAR hypofunction established in SZ for the present 
study.  
 One goal of this project is to increase the translational potential of any 
treatments. Intranasal administration offers a relatively easy, painless method of 
drug delivery. Because OxA – but not OxB – is easily able to diffuse through the 
blood brain barrier, and because OxA has been shown to enhance attentional 
performance, OxA was administered intranasally in the current experiment 
(Kastin & Akerstrom, 1999; Dhuria, Hanson & Frey, 2009; Zajo et al., 2016). 
When compared to oral and intravenous routes of administration, mist or liquid 
introduced through the nose also allows for more rapid onset of a drug’s effects 
due to rapid uptake through the nasal membrane (Thorne et al., 2004). In support 
of this, the efficacy of OxA facilitated intranasally surpassed that of OxA 
injections in reversing the effects of sleep deprivation on cognitive performance 
(Deadwyler et al., 2007). By utilizing OxA in this fashion, not only is its role as a 
potential cognition-enhancer in SZ able to be elucidated, but the clinical efficacy 
of intranasal OxA administration can be further explored.  
Because OxA has previously demonstrated the capacity to alleviate 
cognitive impairment in certain conditions, such as in sleep-deprived organisms, 
it might be hypothesized to ameliorate the negative syndrome of SZ more 
effectively than modern antipsychotic medications. Alternatively, levels of ACh, a 
neurotransmitter critical for attention, are elevated in the MK-801 SZ model; 
because of this, it may be that further stimulation of the ACh system with OxA 
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may be detrimental to performance on a number of cognitive measures. To 
further elucidate OxA’s role as a cognitive-enhancing pharmacotherapy in the 
context of SZ, following training on a previously-validated sustained attention 
task, the effects of various doses of intranasal OxA were examined in tandem 
with MK-801 injections (McGaughy & Sarter, 1995). In this attentional paradigm, 
subjects were required to correctly differentiate between signal and non-signal 
trials (wherein a brief flash of a visual stimulus either does or does not occur) 
during varying periods of time in order to attain reinforcement. We anticipated 
that, in the absence of OxA, attentional performance would be significantly 
impaired for rats given MK-801. By intranasally administering OxA following MK-
801 injections, OxA’s capacity to ameliorate the treatment-resistant cognitive 
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Chapter 2. Methods and Results 
Methods 
Subjects 
12 male Fischer 344 Brown Norway F1 hybrid rats, bred at Charles River 
Laboratories (Wilmington, MA) and weighing between 250 and 350 g at the 
beginning of behavioral training, were utilized throughout the duration of the 
experiment. All behavioral testing occurred at least six days per week between 
the hours of 9AM and 4PM. Rats were housed in pairs throughout the entirety of 
the protocol and were allotted ad libitum access to rodent chow, but they were 
placed on a water restriction schedule to establish tap water as a reinforcer for 
accurate performance in the task. On testing days, rats were given access to a 
water bottle for ten minutes following their time in the task and they received 20 
minutes of water access on days when they were not tested.  
Apparatus 
Each rat was trained in one of 12 operant boxes from Med Associates 
Inc., with all task procedures and data collection controlled by MedPC IV 
software (Georgia, VT). Each box consisted of an intelligence panel with left and 
right retractable levers, access to a water dipper with a 0.01 ml cup, and a 
stimulus light centralized above the water port. A house light was situated on the 
opposite wall facing the intelligence panel and remained illuminated throughout 
the testing session. Each box was located inside of a sound-attenuating 
chamber.  




Rats trained in three phases to reach criterion performance in the 
sustained attention task. In the initial stage, rats were shaped to press the right 
and left levers approximately equally to maximize reinforcement. In order to 
protect against the development of side bias, responses were reinforced on a 
fixed ratio (FR1) schedule, with the stipulation that if the rat pressed one lever 
five consecutive times, it needed to press the other lever to receive reward 
access. A lever press that met this criterion led to the 0.01 ml water dipper being 
raised for three seconds. Once they attained 120 total rewards over a span of 
three days, the rats were moved to the attention task with correction trials.  
 In this second phase of training, rats were shaped to discriminate between 
signals (illumination of the central panel light for one second) and non-signals 
(the central panel light did not illuminate). The inter-trial interval (ITI) was 12±3 s, 
randomized to prevent possible anticipation of the commencement of a new trial. 
After the ITI, a signal was presented or there was no illumination of the central 
panel light and then both levers were extended for three seconds. The rules of 
the task were counterbalanced such that half of the rats were trained to press the 
right lever to indicate detection of the 1 s signal and press the left lever in the 
absence of this light; conversely, for the other half of the rats, a left lever press 
was rewarded in signal trials and a right lever press was reinforced in non-signal 
trials. If the rats responded incorrectly – that is, pressing the signal lever when no 
signal is presented (false alarm), pressing the non-signal lever when a signal is 
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presented (miss), or by failing to press altogether within 3 sec of when the levers 
were inserted into the chamber (omission) – a correction trial ensued. The 
correction trial was identical to the previous trial. If the rat made three 
consecutive incorrect lever presses during correction trials, a forced trial occurred 
wherein only the correct lever was extended into the chamber. The central panel 
light remained illuminated during forced trials that resulted from errors on signal 
trials. These trials only ended once the correct lever was pressed or 90 seconds 
had passed. After the rat correctly identified the presence (hit) and absence 
(correct rejection) of the signal light at a rate of 70% or higher for three 
consecutive days, they progressed to the final version of the task.  
In the last phase of training, rats were trained to detect signals of varying 
durations – 500, 100, and 25ms – without the inclusion of correction trials. While 
the 500 ms is not difficult to detect for rats, correctly identifying the shorter signal 
durations, especially the 25 ms signal, increases the attentional demands of the 
task. Also, variable signal durations increase attentional demands relative to 
sessions with a single signal (Koelga, 1987). Each testing session lasted 
between 35 and 40 minutes and contained 162 trials that were evenly split 
between signal and non-signal trials, with an equal number of trials at each signal 
duration. In order to further augment the degree to which the task taxes 
attentional resources, the ITI was reduced to 9±3 s (McGaughy & Sarter, 1995), 
in order to increase the rate at which rats attended to the presence or absence of 
the visual signal. When rats answered incorrectly in this task, they were not 
allowed access to water at the conclusion of the trial. The behavioral criteria were 
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70% or higher accuracy in identifying both 500 ms signal trials and non-signal 
trials for three successive days. Once rats achieved these criteria, they were 
considered eligible for inclusion in the present experiment. 
MK-801 and OxA preparation 
 MK-801 was purchased from Tocris Bioscience (Bristol, United Kingdom). 
A stock solution of 0.125 mg/kg MK-801 maleate in sterile saline was prepared 
and then pipetted into aliquots and stored in a freezer. The prepared solution was 
utilized within one week of its initial freezing. On a testing day, an aliquot was 
diluted, as needed and only used on that one testing day. 
 OxA was also purchased from Tocris Bioscience. Stock OxA 
concentrations of 5nM and 10 nM were prepared and then frozen and stored for 
the duration of the experiment. All aliquots were thawed immediately before use.  
Drug administration 
  After rats reached criterion task performance, they began a week-long 
period to acclimate to intranasal administration wherein 25 µL saline was 
administered per nare daily. To accomplish this, the saline was pipetted and, with 
the rat’s nostrils oriented upwards, administered in small droplets that were then 
inhaled through the nose. Once the animals had received seven days of 
intranasal saline, drug administration commenced.  
 Drug administration sessions were conducted in a completely within-
subject design, with every subject receiving a total of nine distinct combinations 
of MK-801 (0 mg/kg, 0.075 mg/kg, and 0.125 mg/kg) and OxA (0 nM, 5 nM, and 
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10 nM). During a day of testing, a randomized MK-801-OxA dose pairing was 
selected for each rat to protect against order effects, and at least one day 
separated drug administration sessions to minimize potential interactions from 
prior drug administration. Because the full range of effects induced by MK-801 
are present in less than half an hour after its administration, rats were given 
intraperitoneal injections of one of the three concentrations of MK-801 20 
minutes before testing (Pinault, 2008). After 15 minutes had passed following 
MK-801 injections, 50 µL of either 0 nM, 5 nM, or 10 nM of OxA was 
administered intranasally at a volume of 25 µL per nare. Following a one minute 
acclimation period, rats were then placed in the attention task. This procedure 
was repeated on each day of drug administration until all possible combined 
doses of MK-801 and OxA had been given prior to task performance. 
Data analyses 
 Data analysis entailed calculating the total number of hits and misses at 
the 500, 100, and 25 ms levels as well as correct rejections, false alarms, and 
omissions per testing session. Signal detection accuracy in the task was 
determined by dividing total number of hits at each signal duration by the sum of 
the hits and misses at that specific signal length (h/(h+m)). These calculations, 
considered relative hits, were generated for each MK-801-OxA dose combination 
and signal duration combination per animal. Likewise, the proportion of relative 
correct rejections for non-signal events was determined by dividing total number 
of correct rejections by number of correct rejections and number of false alarms 
(cr/(cr+fa)) for each combination of drug treatment. Repeated-measures 
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ANOVAs and paired-sample t-tests, which were corrected with the Bonferroni 
procedure, were conducted using SPSS (version 23.0, Chicago, IL).  
Results 
 In a 3 (MK-801; 0, 0.075, and 0.125 mg/kg) × 3 (OxA; 0, 5, and 10 nM) × 3 
(signal duration; 500, 100, and 25 ms) repeated measures ANOVA for relative 
hits, MK-801 elicited a main effect on performance in the sustained attention 
task, F(2,22) = 8.231, p = .002 (Figure 1). Paired samples t-tests averaging 
across OxA concentration revealed that, while relative hits at the two lower MK-
801 doses did not differ, signal detection accuracy at 0.125 mg/kg (M = 0.444, 
SD = 0.321) was significantly lower than both 0 mg/kg (M = 0.706, SD = 0.109; 
t(11) = 2.985, p = .012) and 0.075 mg/kg (M = 0.673, SD = 0.259; t(11) = 2.440, p 
= .033). In addition to this main effect, an interaction between OxA dose and 
signal duration was discovered, F(4,44) = 2.712, p = .042 (Figure 2). To further 
elucidate this, one-way ANOVAs averaging across MK-801 dose and examining 
OxA dose as a factor at each signal duration were conducted, but none of these 
analyses yielded significant results.  
 Due to the high omission rates at 0.125 mg/kg of MK-801, examining the 
highest dose with this measure of accuracy may not be appropriate due to 
skewed hit percentages. To address this issue, an additional 2 (MK-801) × 3 
(OxA) × 3 (signal duration) repeated measures ANOVA excluding the largest 
concentration of MK-801 was conducted. The main effect of MK-801 yielded by 
the previous analysis was no longer significant after the removal of the highest 
dose, as 0.075 mg/kg did not impair attentional performance. Despite this failure 
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of MK-801 to induce deficits in signal detection, an MK-801 × OxA × signal 
duration interaction was revealed, F(4,44) = 2.630, p = .047. To assess the basis 
for this interaction, 2 (MK-801) × 3 (signal duration) repeated measures ANOVAs 
were conducted at each of the three OxA concentrations to further elucidate this 
relationship. An MK-801 × signal duration interaction was found after intranasal 
administration of saline, F(2,22) = 6.805, p = .005 (Figure 3). Despite this, when 
determining if performance at any of the three signal durations had significantly 
changed from 0 to 0.075 mg/kg of MK-801, paired samples t-tests exploring this 
relationship yielded no significant outcomes; only during 100 ms trials was signal 
detection accuracy almost significantly decreased from 0 to 0.075 mg/kg 
following intranasal saline exposure, t(11) = 1.971, p = .074. No MK-801 × OxA 
interactions were uncovered at 5 nM or 10 nM of OxA. 
 A 3 (MK-801) × 3 (OxA) repeated measures ANOVA was utilized to 
examine the effects of MK-801 and OxA on the rats’ accuracy on non-signal 
trials. This analysis yielded a main effect of MK-801, F(2,22) = 6.099, p = .008 
(Figure 4). Paired samples t-tests revealed that correct rejections were lower 
following injections of 0.125 mg/kg MK-801 compared to vehicle, t(11) = 2.859, p 
= .016, or to 0.075 mg/kg MK-801, t(11) = 2.382, p = .036. In addition to this main 
effect, there was a significant interaction between MK-801 and OxA, F(4,44) = 
3.063, p = .026. To further elucidate this finding, three repeated measures 
ANOVAs with OxA dose as a factor were conducted for each of the MK-801 
concentrations. These analyses revealed that there was a main effect of OxA in 
the absence of MK-801 (vehicle administration), F(2,22) = 4.350, p = .026. 
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Subsequent paired samples t-tests revealed that relative correct rejections for 
either OxA dose were not significantly different compared with intranasal saline 
administration. However, correct rejection accuracy following 5 nM OxA was 
significantly lower than following 10 nM OxA, t(11) = 2.262, p = .045. One 
potential concern is that the MK-801 × OxA interaction for correct rejections may 
be influenced by completion of relatively few trials at the highest MK-801 dose. 
However, a 2 (MK-801) × 3 (OxA) repeated measures ANOVA, excluding the 
highest MK-801 concentration still yielded a significant MK-801 × OxA 
interaction, F(2,22) = 5.296, p = .013.  
 For omissions, a 3 (MK-801) × 3 (OxA) repeated measures ANOVA 
revealed a main effect of MK-801 concentration, F(2,22) = 5.296, p = .013 
(Figure 5). Omissions after injections of saline were lower than following 
injections of 0.075 mg/kg of MK-801, t(11) = 4.781, p = .001, omissions at 0.075 
mg/kg were less than 0.125 mg/kg, t(11) = 3.138, p = .009, and, lastly, omissions 
after saline injections were substantially less than following 0.125 mg/kg, t(11) = 
5.772, p < .001. The main effect of OxA approached significance (F(2,22) = 
3.116, p = .064), but there was no interaction between the two drugs. Paired-
samples t-tests examining the impact of each dose of OxA on omission rates 
averaging across MK-801 concentration unveiled that trial omissions were almost 
significantly higher after intranasal saline when compared to 5 nM of OxA (t(11) = 
2.176, p = .052) and at 10 nM when compared to 5 nM, t(11) = 2.023, p = .068 
(Figure 6). 
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Chapter 3. Discussion and Conclusion
Discussion 
 The present experiment was designed to test two separate drugs’ effects 
on sustained attentional processing. Firstly, it aimed to reproduce the robust 
finding that MK-801 is a cognition-impairing agent and worsens performance in 
this task. Secondly, this experiment tested whether intranasal OxA administration 
could reduce attentional deficits following NMDAR blockade. In the context of 
psychiatric illness, the current research employed a previously-utilized model of 
SZ, and the potential for OxA – which has been found to demonstrate cognitive-
enhancing qualities – to remediate the negative cognitive symptoms. Overall, it 
was found that the large dose of MK-801 had negative implications for attentional 
performance across all measures of accuracy in the task and that OxA 
administration had no effect or tended to worsen these impairments. Therefore, 
based on the results of this experiment, it is likely that OxA would not be an 
appropriate pharmacotherapy in this SZ model. 
OxA on measures of attentional performance following MK-801 administration 
 The highest MK-801 dose had a profoundly negative impact on hit 
accuracy. OxA itself did not significantly affect signal detection in the task 
following MK-801 administration. Thus, the hypothesis that intranasal OxA could 
reverse attentional impairments following MK-801 administration was not 
supported. Similarly to relative hit performance, MK-801, at the highest 
concentration, significantly reduced the ability of the rats to accurately respond 
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on non-signal trials. Again, once the 0.125 mg/kg concentration was removed 
from the analyses, the ability of MK-801 to induce these attentional deficits 
disappeared. The most interesting findings were the effects following 0, 5, and 10 
nM OxA in the absence of MK-801. After an injection of only saline, correct 
rejections at 5 nM were reduced when compared to 10 nM OxA, but neither dose 
was markedly different when compared to intranasal administration of vehicle. 
The basis for this effect is unclear, but further experiments assessing the spread 
of different intranasal OxA doses among brain regions may be useful in clarifying 
why performance was worse following the lower OxA dose compared with the 
higher OxA dose. There was no notable effect of OxA concentration following 
exposure to MK-801. Finally, MK-801 also elevated omission rates. 
 A likely reason that OxA was unable to alleviate NMDAR blockade-
associated attentional deficits is due to its capacity to promote frontocortical ACh 
release. Lateral hypothalamic orexinergic cells stimulate basal forebrain 
cholinergic neurons, and augmenting activity at these receptors appears to 
further exacerbate the already-overactive cholinergic system present in SZ-
afflicted individuals. As was previously detailed, a surplus of cholinergic input in 
the cortex leads to the overstimulation of various sensory and perceptual 
systems by weakening the brain’s ability to filter irrelevant environmental stimuli, 
and it is likely that elevated frontocortical ACh, in congruence with overstimulated 
PFC pyramidal cells resulting from NMDAR hypofunction, worsens cognitive 
performance (Donoghue & Carroll, 1987; Perry & Perry, 1995; Homayoun & 
Moghaddam, 2007). As a consequence of excessive excitatory 
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neurotransmission in both cortical and subcortical regions, it may be that the rats’ 
visual system was stimulated to such an extent that there was an impairment in 
filtering whether or not a visual cue was presented. This notion is supported by 
the finding that, while relative hits were not impaired by combinations of MK-801 
and OxA, high concentrations of exogenous OxA, in congruence with NMDAR 
blockade, appeared to somewhat worsen relative correct rejections, leading them 
to err on the side of signal detection. Drugs that primarily act at α7-nAChRs, 
which facilitate the activity of inhibitory septo-hippocampal GABAergic 
innervations of the basal forebrain, demonstrate promise in alleviating SZ 
symptoms; however, perhaps because OxA promotes ACh release at other 
cholinergic receptor sites, it does not possess this therapeutic effect. 
  As MK-801 concentration increased, omission rates also increased in a 
dose-dependent manner. Omissions were elevated at 0.075 mg/kg of MK-801 
when compared to injections of saline, and omissions were higher at 0.125 
mg/kg than at 0.075 mg/kg. A near-significant main effect of OxA revealed that 
rats tended to omit slightly more often after intranasal saline and 10 nM of OxA 
when compared to 5 nM, suggesting that perhaps small concentrations of OxA 
help to protect against NMDA antagonism-induced elevations in trial omissions. 
While no noteworthy motor aberrations were observed before or shortly after 
engagement in the attention task, it is possible that increased concentrations of 
MK-801 disrupted motor functioning and interfered with movements related to 
lever-pressing (Tricklebank et al., 1989). 
Implications of OxA treatment in SZ 
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 In a SZ model using NMDA receptor blockade, the introduction of 
pharmacotherapies enhancing OxA activity do not improve measures of 
sustained attentional performance. In fact, OxA sometimes further exacerbated 
the adverse impact of MK-801. In neurological conditions wherein frontocortical 
neurotransmission is substantially reduced, such as in Alzheimer’s, ADHD, or 
Parkinson’s disease, OxA and other compounds agonizing these orexin-
releasing neurons have been speculated to alleviate cognitive deficits by 
bolstering the release of monoamines such as DA, ACh, and histamine 
throughout pertinent cortical regions (Fadel, Pasumarthi & Reznikov, 2005; Vittoz 
& Berridge, 2006). The present findings suggest that OxA, while having 
previously been found to either boost cognition or alleviate related deficits in 
following some forms of dysfunctional CNS activity, is not a viable 
pharmacotherapy when attempting to treat the negative symptoms of SZ. Thus, 
although OxA can still be considered a cognition-boosting agent, this beneficial 
quality is not reflected across all disorders and may be, in large part, reliant on 
dampened cholinergic neurotransmission (Zajo et al., 2016). With disorders such 
as SZ, where cortical excitation is elevated, it appears that OxA has little or 
possibly even a negative effect on attention and cognitive processing.  
One potential shortcoming of this study is the effectiveness of the chosen 
doses of MK-801. With 0 nM of OxA, while the high dose of 0.125 mg/kg had an 
extremely profound impact in terms of both impairing accuracy and increasing 
omissions in the attention task, the 0.075 mg/kg concentration failed to induce 
deficits in both of those regards. Previous studies utilizing 0.1 mg/kg or higher 
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have consistently provided findings similar to those generated by this 
experiment in that many facets of cognition, such as attention, learning, and 
working memory, are impaired; however, lower doses, such as 0.05 and 0.075 
mg/kg, have offered mixed results in their cognition-impairing abilities (Hliňáka & 
Krejčıb́, 2002; Howe & Burk, 2007; van der Staay et al., 2011). Therefore, it may 
be that 0.075 mg/kg on its own was too low of a concentration to sufficiently 
block NMDAR function to the extent that it would produce the full impairment in 
attentional performance that is seen quite drastically with the 0.125 mg/kg dose. 
While this may affect the interpretation of the current study in terms of its 
applicability to emulating SZ symptomology, the elevated dose of intranasal OxA 
still reduced attentional capacity, perhaps indicative of OxA’s tendency to further 
worsen the effects of NMDAR inhibition in the cortex. 
Future directions 
 If OxR activation worsens frontocortical hypexcitation induced by NMDAR 
antagonism, it may be the case that reducing the input from these receptors 
could enhance cognition in this and other conditions demonstrating similar 
abnormalities in cortical excitatory neurotransmission. Drugs that target and 
reduce the activation of Ox1Rs and Ox2Rs, for example, could temporarily 
lessen the consequences of hyperfrontality and alleviate some of the cognitive 
deficits seen in SZ and similar disorders. Preliminary findings from our lab have 
shown that, at small concentrations, the Ox2R antagonist TCS-OX2-29 is able to 
transiently improve performance in the sustained attention task in neurotypical 
rats when infused directly into the medial PFC (Tapp, Maness, & Burk, in 
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preparation). These findings, taken with the results from the present experiment, 
provide an impetus to explore the implications of Ox1R or Ox2R blockade on 
attentional and cognitive performance in a similar NMDAR hypofunction model of 
SZ. Additionally, the orexin system is critical for sleep and circadian rhythmicity, 
so the suppression of these neurons may have unforeseen impacts on sleep 
quality and drowsiness that may assuage its beneficial effects on cognitive 
performance. 
 Because the cognition-boosting qualities of OxA are worth further 
elucidation in the context of intranasal administration due to ease of self-
administration and how quickly it elicits its effects, it may be useful to examine its 
therapeutic effects following widespread loss of cholinergic neurons. The 
tendency for OxA to worsen measures of accuracy in the attention task in rats 
treated with MK-801, particularly with correct rejections, indicates that OxA may 
be exerting much of its influence on basal forebrain cholinergic inputs to the 
cortex and subcortex. One method that could verify this synergistic orexinergic-
cholinergic interaction, similarly to a study by Zajo, Fadel and Burk (2016) 
wherein intracerebroventricular infusions of OxA were able to alleviate attentional 
deficits following basal forebrain corticopetal lesions, would involve disrupting 
BFCS functionality – either with a cholinergic antagonist or the cholinergic 
immunotoxin 192 IgG-saporin – and administering OxA intranasally preceding 
placement in the operant task. In doing so, the influence of lateral hypothalamic 
orexinergic efferents on the basal forebrain would be better understood, and the 
therapeutic potential of nasal OxA administration would be further established in 
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the context of Alzheimer’s and Parkinson’s diseases, wherein cholinergic 
neurotransmission is compromised. 
Conclusion 
   In an MK-801 model of SZ, increased activation of orexin receptors 
through the introduction of intranasal OxA did not alleviate MK-801-induced 
attentional deficits. This failure of OxR stimulation to enhance cognition in this 
paradigm is likely due to its tendency to worsen the cognitive and perhaps 
perceptual disturbances resulting from a failure of NMDAR and GABAR 
regulation of excitatory neurotransmitter release in the PFC and other cortical 
regions. Additionally, because of orexinergic innervation onto basal forebrain 
cholinergic neurons, hypercholinergia was likely aggravated after OxA exposure, 
failing to improve measures of attentional accuracy. These findings further 
discern the role of this neuropeptide as a “cognition-enhancer” in certain 
circumstances and not others, and they also suggest that alleviating the 
abnormal cognition and behaviors seen in SZ may lie in the reduction, rather 
than promotion, of frontal lobe stimulation. In this regard, Ox1R and/or Ox2R 
antagonists may provide a unique   advantage in this model by assuaging cortical 
hyperexcitation. In a similar vein, further attempts to explore the potential for 
drugs that strengthen OxR activity as a form of pharmacotherapy to treat 
disorders with a cognitive component would likely yield more successful results in 
the framework of dampened cortical excitation. In particular, cognitive decline 
stemming from loss of cholinergic fibers, which occurs during neurodegeneration 
and is especially aggravated in dementing states, may benefit from intranasal 
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OxA administration. Therefore, while not advantageous in a rodent model of SZ, 

























Figure 1. Hit percentages at each dose of OxA (0, 5, and 10 nM) across the three 
concentrations of MK-801 (0, 0.075, and 0.125 mg/kg). MK-801 impaired overall 
performance on this measure at 0.125 mg/kg, but not at 0.075 mg/kg. While 
there was a significant interaction between MK801, OxA, and signal duration 
when excluding the largest MK-801 dose, there were no differences in signal 
detection accuracy between the three OxA concentrations at 0 and 0.075 mg/kg. 
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Figure 2. Hit percentages at each signal duration (500, 100, and 25 ms) at the 
three doses of OxA averaged across MK-801 concentration. There was a 
statistically significant interaction between OxA and signal duration, which was 
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Figure 3. Hit percentages at each signal duration (500, 100, and 25 ms) at 0 
mg/kg and 0.075 mg/kg of MK-801 following intranasal saline administration. 
There was a statistically significant interaction between MK-801 and signal 
duration. Despite this, there were no substantial changes in signal detection 












Figure 4. Correct rejection percentages at each of the three OxA doses across 
the three concentrations of MK-801.Similarly to relative hits, MK-801 impaired 
overall performance on this measure at 0.125 mg/kg, but not at 0.075 mg/kg. At 0 
mg/kg of MK-801, the identification of non-signal trials following 5 nM of OxA was 
impaired when compared to performance at 10 nM. From 0 mg/kg to 0.075 
mg/kg, correct rejections after exposure to 10 nM of OxA decreased while 5 nM 
prevented a significant impairment in performance. At 0.075 mg/kg of MK-801, 












Figure 5. Omission rates at each of the three OxA doses across the three 
concentrations of MK-801. As the dose of MK-801 was augmented, trial 
omissions dose-dependently increased despite OxA administration. While 
omissions for 0 nM and 10 nM of OxA were elevated from 0 to 0.075 mg/kg of 
MK-801, 5 nM of OxA protected against this significant increase, but trial 









Figure 6. Omission rates following administration of 0, 5, and 10 nM of OxA 
averaged across MK-801 concentration. When considering trial omissions, the 
main effect of OxA approached significance, and follow up tests revealed that 
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